Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $230

Benzinga · 1d ago
Evercore ISI Group analyst Cory Kasimov maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $220 to $230.